Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB

[1]  W. Frontera,et al.  IKKβ/NF-κB Activation Causes Severe Muscle Wasting in Mice , 2004, Cell.

[2]  G. Cline,et al.  Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. , 2004, Diabetes.

[3]  K. Rajewsky,et al.  Conditional disruption of IκB kinase 2 fails to prevent obesity-induced insulin resistance , 2004 .

[4]  J. Hoofnagle,et al.  A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis , 2004, Hepatology.

[5]  K. Rajewsky,et al.  Conditional disruption of IkappaB kinase 2 fails to prevent obesity-induced insulin resistance. , 2004, The Journal of clinical investigation.

[6]  M. Desai,et al.  Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.

[7]  L. Tartaglia,et al.  Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.

[8]  J. Capeau,et al.  Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. , 2003, Biochemical and biophysical research communications.

[9]  U. Smith,et al.  Interleukin-6 (IL-6) Induces Insulin Resistance in 3T3-L1 Adipocytes and Is, Like IL-8 and Tumor Necrosis Factor-α, Overexpressed in Human Fat Cells from Insulin-resistant Subjects* , 2003, Journal of Biological Chemistry.

[10]  S. Shoelson,et al.  Inflammation and the IKKβ/IκB/NF-κB axis in obesity- and diet-induced insulin resistance , 2003, International Journal of Obesity.

[11]  G. Hotamisligil,et al.  Inflammatory pathways and insulin action , 2003, International Journal of Obesity.

[12]  T. Zimmers,et al.  Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. , 2003, Diabetes.

[13]  B. Neuschwander‐Tetri,et al.  Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR‐γ ligand rosiglitazone , 2003, Hepatology.

[14]  L. Kuller,et al.  Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. , 2003, American journal of physiology. Endocrinology and metabolism.

[15]  E. Freedland,et al.  Inflammation and its relationship to insulin resistance, type 2 diabetes mellitus, and endothelial dysfunction. , 2003, Metabolic syndrome and related disorders.

[16]  Joachim Spranger,et al.  Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. , 2003, Diabetes.

[17]  A. Mokdad,et al.  Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. , 2003, JAMA.

[18]  W. Ebstein.  Invited comment on W. Ebstein: On the therapy of diabetes mellitus, in particular on the application of sodium salicylate. , 2002, Journal of molecular medicine.

[19]  S. Shoelson.  JMM – Past and Present , 2002, Journal of Molecular Medicine.

[20]  A. Häkkinen,et al.  Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. , 2002, The Journal of clinical endocrinology and metabolism.

[21]  K. Petersen,et al.  Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. , 2002, The Journal of clinical investigation.

[22]  S. Haffner,et al.  Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. , 2002, Diabetes.

[23]  U. Visco-Comandini,et al.  Metformin in non-alcoholic steatohepatitis , 2002, The Lancet.

[24]  Michael Karin,et al.  Reversal of Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of Ikkβ , 2001, Science.

[25]  G. Shulman,et al.  Prevention of fat-induced insulin resistance by salicylate. , 2001, The Journal of clinical investigation.

[26]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[27]  A. Fischer,et al.  Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. , 2001, Blood.

[28]  J. Radziuk,et al.  Insulin sensitivity and its measurement: structural commonalities among the methods. , 2000, The Journal of clinical endocrinology and metabolism.

[29]  D. Moller.  Potential Role of TNF-α in the Pathogenesis of Insulin Resistance and Type 2 Diabetes , 2000, Trends in Endocrinology & Metabolism.

[30]  A. Häkkinen,et al.  Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. , 2000, Diabetes.

[31]  Nanxin Li,et al.  [25] Signaling pathways leading to nuclear factor-κB activation , 2000 .

[32]  D. Moller.  Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. , 2000, Trends in endocrinology and metabolism: TEM.

[33]  M. Karin,et al.  Signaling pathways leading to nuclear factor-kappa B activation. , 2000, Methods in enzymology.

[34]  Michael Karin,et al.  Positive and Negative Regulation of IκB Kinase Activity Through IKKβ Subunit Phosphorylation , 1999 .

[35]  M. Mann,et al.  IκB Kinase (IKK)-Associated Protein 1, a Common Component of the Heterogeneous IKK Complex , 1999, Molecular and Cellular Biology.

[36]  M. A. Crook,et al.  Is Type II diabetes mellitus a disease of the innate immune system? , 1998, Diabetologia.

[37]  S. Ito,et al.  Interleukin 1β and interleukin 6, but not tumor necrosis factor α, inhibit insulin‐stimulated glycogen synthesis in rat hepatocytes , 1998 .

[38]  Zhaodan Cao,et al.  NF-κB-inducing kinase activates IKK-α by phosphorylation of Ser-176 , 1998 .

[39]  D. Goeddel,et al.  NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  S. Ito,et al.  Interleukin 1beta and interleukin 6, but not tumor necrosis factor alpha, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes. , 1998, Hepatology.

[41]  C. Burant,et al.  Troglitazone action is independent of adipose tissue. , 1997, The Journal of clinical investigation.

[42]  Seamus J. Martin,et al.  Suppression of TNF-α-Induced Apoptosis by NF-κB , 1996, Science.

[43]  D. Green,et al.  Suppression of TNF-alpha-induced apoptosis by NF-kappaB. , 1996, Science.

[44]  M. Karin,et al.  Phosphorylation of I kappa B alpha precedes but is not sufficient for its dissociation from NF-kappa B , 1995, Molecular and cellular biology.

[45]  M. Papa,et al.  Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. , 1993, The Journal of biological chemistry.

[46]  B. Spiegelman,et al.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.

[47]  J. Abrams,et al.  Strategies of Anti‐Cytokine Monoclonal Antibody Development: Immunoassay of IL‐10 and IL‐5 in Clinical Samples , 1992, Immunological reviews.

[48]  J. Abrams,et al.  Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice. , 1990, Journal of immunology.

[49]  R. Palmiter,et al.  Introns increase transcriptional efficiency in transgenic mice. , 1988, Proceedings of the National Academy of Sciences of the United States of America.